Kevin Conroy, Chairman & CEO of Exact Sciences, shared a post on LinkedIn:
“Our MRD test, Oncodetect, is now covered by Medicare for serial use in patients with stage II, III, and resectable stage IV colorectal cancer. This decision means even more patients can benefit from earlier, more precise answers about their care. Thankful for the Exact Sciences team whose work made this possible, and proud of what it means for patients.”
Read Full Article on Exact Sciences.
Read More About Immunotherapy for CRC on OncoDaily.
